Skip to content
Screener

Charles River Laboratories CRL Debt - Unamortized Discount (Premium) and Issuance Costs, Net

Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies

Revvity logo
RevvityRVTY
$15.88M-17.9%
IQVIA logo
IQVIAIQV
$82M-1.2%
Danaher logo
DanaherDHR
$130M+42.9%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.68B+71.7%
Enterprise value$15.48B+54.6%
P/S3.2×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemJune 27, 2026December 27, 2025
Total debt and finance leases2,637,3812,152,221
Less:
Current portion of long-term debt5,460166
Current portion of finance leases1,1663,228
Current portion of long-term debt and finance leases6,6263,394
Long-term debt and finance leases2,630,7552,148,827
Debt discount and debt issuance costs(10,770)(12,467)
Long-term debt, net and finance leases$2,619,985$2,136,360

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's debt - unamortized discount (premium) and issuance costs, net?
Charles River Laboratories (CRL) reported debt - unamortized discount (premium) and issuance costs, net of -$10.77M in Q2 2026.
How has Charles River Laboratories's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
Charles River Laboratories's debt - unamortized discount (premium) and issuance costs, net increased by 24.0% year-over-year, from -$14.16M to -$10.77M.
What is the long-term trend for Charles River Laboratories's debt - unamortized discount (premium) and issuance costs, net?
Over 5 years (2020 to 2025), Charles River Laboratories's debt - unamortized discount (premium) and issuance costs, net has grown at a -2.8% compound annual growth rate (CAGR), from -$14.35M to -$12.47M.
What does debt - unamortized discount (premium) and issuance costs, net mean?
This represents the net adjustment to the face value of debt, accounting for original issue discounts, premiums, and capitalized debt issuance costs. These amounts are amortized over the life of the debt instrument to reflect the effective interest rate. It is essential for reconciling the carrying value of debt to its face value.

Ask your AI about Charles River Laboratories's debt - unamortized discount (premium) and issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude